Recent advances in the drug treatment of inflammatory bowel disease (IBD) have paralleled
our understanding of the pathophysiology of ulcerative colitis and Crohn’s disease. Several …

The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care.
Nonetheless, not all patients require biological therapy. Selection of patients depends on …

… to its well-known role in septic shock, it has been implicated in the pathogenesis of chronic
processes such as autoimmunity, graft-versus-host disease, rheumatoid arthritis, Crohn’s …

The inflammatory bowel diseases Crohn's disease and ulcerative colitis are common, chronic
disorders that cause abdominal pain, diarrhea, and gastrointestinal bleeding. To identify …

Background Enterocutaneous fistulas are a serious complication of Crohn's disease and are
difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, has …

Crohn’s disease and ulcerative colitis, the two common forms of inflammatory bowel disease
(IBD), affect over 2.5 million people of European ancestry, with rising prevalence in other …

Background Studies in animals and an open-label trial have suggested a role for antibodies
to tumor necrosis factor α, specifically chimeric monoclonal antibody cA2, in the treatment of …

The discovery of a series of genetic and serological markers associated with disease
susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an …

Several risk factors for Crohn's disease have been identified in recent genome-wide association
studies. To advance gene discovery further, we combined data from three studies on …

We undertook a meta-analysis of six Crohn's disease genome-wide association studies (GWAS)
comprising 6,333 affected individuals (cases) and 15,056 controls and followed up the …